NASDAQ: REGN
Regeneron Pharmaceuticals Inc Earnings Dates, Reports, Calls

Regeneron Pharmaceuticals earnings were $4.3B for the trailing 12 months ending Jun 30, 2026, with 0.4% growth year over year. The latest REGN earnings report on Jun 30, 2026 announced Q2 2026 earnings of $1.3B, up 78.3% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, REGN reported annual earnings of $4.5B, with 2.1% growth. The next REGN earnings date is Oct 27, 2026.

REGN past earnings growth

How has REGN's earnings growth performed historically?

Company
0.43%
Industry
17.53%
Market
93.61%
REGN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
REGN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
REGN's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

REGN earnings history

Current Revenue
$15.5B
Current Earnings
$4.3B
Current Profit Margin
27.9%
REGN's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

REGN Return on Equity

Current Company
13.8%
Current Industry
-13.6%
Current Market
31.1%
REGN's Return on Equity (13.8%)... subscribe to Premium to read more.
High Return on Equity Performance

REGN Return on Assets

Current Company
10.6%
Current Industry
-10.2%
REGN is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when REGN announces earnings.

REGN Return on Capital Employed

Current Company
14.42%
Current Industry
-6.7%
REGN's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

REGN vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
REGN$5.75B$4.33B-6.56%$41.94
ARGX$2.03B$1.95B+26.02%$31.53
MRNA-$2.85B-$3.15BN/A-$7.99
RVMD-$1.69B-$1.77BN/A-$8.85
ONC$1.16B$655.71MN/A$0.45

REGN earnings dates

Next earnings date
Oct 27, 2026

Regeneron Pharmaceuticals Earnings Reports & History FAQ

What were Regeneron Pharmaceuticals's earnings last quarter?

On REGN's earnings call on Jul 30, 2026, Regeneron Pharmaceuticals (NASDAQ: REGN) reported Q2 2026 earnings per share (EPS) of $12.62, up 4.68% year over year. Total REGN earnings for the quarter were $1.30 billion. In the same quarter last year, Regeneron Pharmaceuticals's earnings per share (EPS) was $13.24.

If you're new to stock investing, here's how to buy Regeneron Pharmaceuticals stock.

When does Regeneron Pharmaceuticals report earnings?

The next REGN earnings call is Oct 27, 2026. Add REGN to your watchlist to be reminded of Regeneron Pharmaceuticals's next earnings date.

Is Regeneron Pharmaceuticals profitable or losing money?

As of the last Regeneron Pharmaceuticals earnings report, Regeneron Pharmaceuticals is currently profitable. Regeneron Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $4.33 billion, a 2.91% decrease year over year.

What was REGN's earnings growth in the past year?

As of Regeneron Pharmaceuticals's earnings date in Jul 30, 2026, Regeneron Pharmaceuticals's earnings has grown 0.43% year over year. This is 17.1 percentage points lower than the US Biotechnology industry earnings growth rate of 17.53%. REGN earnings in the past year totalled $4.33 billion.

What are Regeneron Pharmaceuticals's earnings expectations?

The current EPS estimate for Regeneron Pharmaceuticals's earnings report in Oct 27, 2026 is $12.89.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.